ABVX:EPA
Abivax SA
€ ८४.३५
arrow_upward
+१.३२%(+१.१०) 1D
अक्टोबर २१, १७:३७:०१ GMT+२ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€ ८३.२५
High
€ ८५.८०
Low
€ ८२.२५
Mkt. cap
७.३८ अरब
Avg. vol.
१.२२ लाख
Volume
०.००
52-wk high
€ १३९.००
52-wk low
€ ६०.४५
EPS
-€ ५.२०
Shares outstanding
८.७५ करोड
No. of employees
९८
Open
€ ८३.२५
High
€ ८५.८०
Low
€ ८२.२५
Mkt. cap
७.३८ अरब
Avg. vol.
१.२२ लाख
Volume
०.००
52-wk high
€ १३९.००
52-wk low
€ ६०.४५
EPS
-€ ५.२०
Shares outstanding
८.७५ करोड
No. of employees
९८
News stories
From web sources and news partners
TradingView
·
२ घण्टा पहिले
How Are Dow, S&P 500, Nasdaq Futures Trading After META, TSLA Earnings?
GuruFocus
·
४८ मिनेट पहिले
Innventure, Inc. (NASDAQ: INV) Securities Investigation: Investo
HDFC Sky
·
१ घण्टा पहिले
US Markets Rally as Tech, AI Stocks Jump; Dow Gains 360
CNBC
·
१३ घण्टा पहिले
Why the stock market’s fragile calm faces a major test starting Friday
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees९८
Founded२०१३ डिसेम्बर ४
Headquarters-
Sector-
Websiteabivax.com